AHG has dropped 25% in a week and 31% over the past month, closing at $1.045 — yet the data shows almost no meaningful short-side pressure driving it.
The most striking feature of Akso Health Group's lending market is how detached it is from the price action. Borrow availability is essentially unlimited — the lending pool shows more than 211,000 shares available against roughly 22,000 shorted, putting availability at levels the data system records simply as maxed out. Short interest itself is tiny at just 0.004% of the free float, and it has been falling steadily — down 26% on the week and 37% over the past month. This is not a stock under short-side siege. What makes the borrow picture slightly unusual is cost: at 32.9% annualised, the fee to borrow AHG is genuinely elevated for a stock this lightly shorted. That rate more than doubled over the past month, from around 12% in mid-June to where it is now. It is a quirk rather than a signal — the CTB history shows it briefly above 50% in late May before settling into the 30s — but it does suggest the lending infrastructure around this name is thin even when the volume of actual shorting is negligible.
The ORTEX short score sits at 41.1, roughly in the middle of its range and barely moving — it has tracked between 40.4 and 42.3 over the past two weeks. That is consistent with a stock where the short-side story is stable and unremarkable. The days-to-cover reading, by contrast, ranks in the 92nd percentile of the universe, which reflects how thinly traded the float is rather than any alarming short build. There are no options data or analyst coverage to lean on here, and the only valuation figure available — an enterprise value north of $595 million — does not reconcile cleanly with a stock trading near $1 on a market cap that appears negligible, so that figure is best treated with caution.
The one institutional holder on record, Webao Limited, held a 31% stake as of late March. That data is now stale at 141 days, but the concentration is notable: a single holder controlling nearly a third of outstanding shares in a micro-cap name leaves the public float extremely thin. Earnings history adds a further layer of context. The most recent print on August 14 produced a 7% one-day drop. The prior release in late July delivered a 5% gain on the day and a 10% five-day follow-through — suggesting the stock can swing hard in either direction around results, with no stable pattern.
The broader picture is of a micro-cap Nasdaq-listed Chinese healthcare name losing ground steadily without a clear short-driven catalyst. The price has shed roughly a third of its value since late July, borrow is plentiful, and shorts are actually exiting rather than pressing. What to watch is whether the concentrated ownership structure or any news from Webao shifts the float dynamics — because in a name this thinly traded, ownership flows matter far more than the lending market.
See the live data behind this article on ORTEX.
Open AHG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
